Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
AssigneePrecision BioSciences, Inc.
InventorsJanel Lape, James Jefferson Smith
Life of this patent
Estimating the term…
Abstract
The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within a Hepatitis B virus (HBV) genome. The engineered meganucleases can exhibit at least one optimized characteristic, such as enhanced specificity and/or efficiency of indel formation, when compared to previously described HBV meganucleases. Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, nucleic acids encoding engineered meganucleases, and the use of such compositions for treating HBV infections or hepatocellular carcinoma.
Claims15
An engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO:
- 10 within a Hepatitis B virus genome, wherein said engineered meganuclease comprises a first subunit and a second subunit, wherein said first subunit binds to a first recognition half-site of said recognition sequence and comprises a first hypervariable (HVR1) region having at least 80% sequence identity to residues 215-270 of any one of SEQ ID NOs:
- 12-17, and wherein said second subunit binds to a second recognition half-site of said recognition sequence and comprises a second hypervariable (HVR2) region having at least 80% sequence identity to residues 24-79 of any one of SEQ ID NOs:
- 12-17.
2-30. (canceled)
33-35. (canceled)
37-45. (canceled)
47-54. (canceled)
56-63. (canceled)
(canceled)
67-86. (canceled)
Dependencies are inferred from the claim text.